Appenzell, Switzerland, November 09, 2009 / b3c newswire / - TRIN Pharma GmbH, specializing in the development of small molecule drugs for tumor treatment, has announced that effective October 6, 2009, Dr. Stefan Wohlfeil has been appointed new CEO of TRIN Pharma.
Stefan Wohlfeil previously held the position of Chief Medical Officer at TRIN Pharma. The change in management takes place at a time, where TRIN Pharma is moving its lead molecule TRIN 2755 into Phase I clinical development.
Dr. Rudolf Reiter, who held the position previously in addition to his role as CEO of Ergonex, will now focus entirely on his responsibility for Ergonex. Rudolf Reiter commented: "I am pleased to pass the leadership of TRIN Pharma on to Stefan Wohlfeil who has the right expertise to drive the clinical development of TRIN 2755. This will allow me to direct my full attention to Ergonex and the development of Terguride."
Stefan Wohlfeil said: "I am excited to take over from Rudolf Reiter at a time where our lead molecule is entering clinical development. I would like to thank Rudolf for his excellent work and many contributions during the build-up phase of TRIN Pharma."
About TRIN Pharma – www.trinpharma.com
TRIN Pharma GmbH develops new small molecule drugs for effective tumor treatment. The research is focused on innovative compounds with proprietary molecular structure, high selectivity and potent anti-tumor activity. TRIN Pharma’s business objective is the development of its molecules into clinical studies and commercialization. TRIN Pharma is financed by High Tech Private Equity, Düsseldorf, Germany.
Dr. Stefan Wohlfeil, MD
Chief Executive Officer
TRIN Pharma GmbH
Tel.: +41-(0)71-788 4063